Interpreting | 2009.12.08
Epizyme Closes $40M Series B Financing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M. Epizyme initially announced a $32M round led by Bay City Capital (BCC) in September of this year. NEA joins an investor group that includes BCC, Amgen Ventures, Astellas Venture, MPM Capital and Kleiner
For more information, please visit
http://www.businesswire.com/news/home/20091208006366/en
